Vise Technologies’s Travere Therapeutics TVTX Stock Holding History

Vise Technologies’s Portfolio TVTX Stock Details TVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$343K	Buy	+5,817	New	+$355K	﹤0.01%	1611

Other funds holding TVTX

Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

Hennion & Walsh Asset Management Parsippany, New Jersey $3.42B AUM 25.82% 1-Year Est. Return

Essex Investment Management Boston, Massachusetts $675M AUM 61.81% 1-Year Est. Return

Insight Wealth Strategies San Ramon, California $1.01B AUM 28.81% 1-Year Est. Return

Oak Ridge Investments Chicago, Illinois $1.68B AUM 48.52% 1-Year Est. Return

OpenArc Corporate Advisory Atlanta, Georgia $8.86B AUM 19.31% 1-Year Est. Return

Virginia Retirement Systems Richmond, Virginia $16.3B AUM 35.33% 1-Year Est. Return

Sigma Planning Corp Ann Arbor, Michigan $3.88B AUM 23.38% 1-Year Est. Return

Profund Advisors Bethesda, Maryland $3.48B AUM 66.96% 1-Year Est. Return

Burney Company Reston, Virginia $3.66B AUM 27.59% 1-Year Est. Return

Vise Technologies's TVTX Position: Q3 2026 in Review

Vise Technologies opened a new position in Travere Therapeutics (TVTX) in Q3 2026: 5,817 shares worth $343K. The stake represents ﹤0.01% of the portfolio and ranks #1611 among its holdings.

62 funds tracked by Wall St. Rank hold TVTX as of Q3 2026.

Vise Technologies held 5,817 shares of Travere Therapeutics worth $343K as of Q3 2026.
Travere Therapeutics was a new Vise Technologies position in Q3 2026.
Travere Therapeutics made up ﹤0.01% of Vise Technologies's portfolio in Q3 2026, its #1611 holding.
62 funds tracked by Wall St. Rank held Travere Therapeutics as of Q3 2026.

Based on Vise Technologies's 13F filing for Q3 2026, filed 29 Oct 2026.